QLS-111-FDC

· Qlaris Bio, Inc.

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for QLS-111-FDC, covering 2026-04-03 to 2026-07-29. Get the full timeline:

Most recent: Clinical Trial Update: Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension [Phase 2, Phase 3]